Palliative care--a shifting paradigm.

n engl j med 363;8 nejm.org august 19, 2010 781 Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates 4. with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53. Schwartzentruber DJ, Lawson D, Richards J, et al. A phase III 5. multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009;27:Suppl:18s. abstract. Prieto PA, Yang JC, Sherry RM, et al. Cytotoxic T lympho6. cyte-associated antigen 4 blockade with ipilimumab: long-term follow-up of 179 patients with metastatic melanoma. J Clin Oncol 2010;28:Suppl:15s. abstract. Rosenberg SA, Dudley ME. Adoptive cell therapy for the 7. treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21:233-40. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evalu8. ation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: 9. proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009;27:Suppl:461s. abstract. Sznol M, Powderly JD, Smith DC, et al. Safety and antitumor 10. activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO4538) in patients with advanced refractory malignancies. J Clin Oncol 2010;28:Suppl. abstract. (Accessed July 28, 2010, at http:// meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/2506.)